NRIX.US Nurix Therapeutics Inc

Healthcare Biotechnology USA Stocks
15.48 USD
Close of Nov 15, 2026
12.61 28.23
Market cap
USD 1.69B
P/E
6.4x
P/B
1.74x
ROE
51.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.

Is NRIX.US undervalued?

Graham number
Price15.48
Graham value22.02
Discount29.7%

NRIX.US trades 29.7% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Nurix Therapeutics Inc fundamental analysis

No fundamental analysis for Nurix Therapeutics Inc yet.

Nurix Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Nurix Therapeutics Inc

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's ty…

Full company profile